GRDN

Guardian Pharmacy Services has had a strong run over the past year, which puts fresh attention on a simple question for investors: Is the current share price aligned with what the business can generate in cash over time, based on its underlying pharmacy…

Adjusted EBITDA surged 19% despite IRA pricing headwinds and fuel cost pressures.

Why Guardian Pharmacy Services’ latest earnings matter for investors Guardian Pharmacy Services (GRDN) reported second quarter 2026 results on 6 August with higher net income versus a year earlier and updated full year guidance that points to higher expected revenue and adjusted EBITDA.

In the past week, Guardian Pharmacy Services, Inc.

Guardian Pharmacy Services (NYSE:GRDN) reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation…

Guardian Pharmacy Services, Inc. (NYSE:GRDN) reported second-quarter 2026 results and increased its financial guidance for the full year, sending shares up around 3.

Guardian Pharmacy Services Inc (GRDN) boosts full-year outlook on 23% adjusted EBITDA growth while navigating IRA pricing pressures and maintaining a robust M&A pipeline.

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +11.54% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ATLANTA, August 06, 2026--Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the second quarter ended June 30, 2026.